BioCryst Pharmaceuticals, Inc. announced that the company has appointed Steve Aselage to its board of directors. Mr. Aselage most recently served as chief executive officer of Retrophin Pharmaceuticals, which he joined in 2012. He replaces Fred Cohen, who has served on the BioCryst board of directors since 2013. The board also appointed Mr. Aselage to serve on the Compensation Committee and the Commercial Committee effective upon his election to the Board.